RESEARCH GROUP

Pediatric Oncology Translational Research

PRINCIPAL INVESTIGATOR

KEY INTERESTSPersonalized/Precision Pediatric Oncology • Pediatric Immuno-oncology • Metronomic Chemotherapy • Long Term Follow Up

RESEARCH OBJECTIVES Personalized precision pediatric oncology based on comprehensive assessment of the tumor and the host.

Decreasing the disease and treatment related morbidity and mortality while studying long term survivors and running juvenile animal studies for new anticancer medicines.

CSF proteomic project for children with brain tumors and leukemia and NHL. Analysis of possible biomarkers.

RESEARCH FOCUSThe Pediatric Oncology Translational Research group (POTR) is focused on personalized, precision pediatric oncology using up to date theranostic approaches in order to increase survival and decrease long term morbidity and sequelae from the disease and necessary therapies. Rational incorporation of new anticancer drugs and immune therapies into earlier lines of treatment based on comprehensive DNA, RNA and proteomic analyses of the tumor and the patient as the host.Establishment of functional regional model for long term follow up with transition of care from pediatric to adult services as the platform to study long term toxicities, risk factors and

ST. ANNE‘S UNIVERSITY HOSPITAL BRNOINTERNATIONAL CLINICAL RESEARCH CENTER

Prof. MUDr. Jaroslav ŠTĚRBA, Ph.D.

Professor at Faculty of Medicine, Masaryk University E-mail: jaroslav.sterba@fnusa.czPhone: (+420) 532 234 600

CREATING THE FUTURE OF MEDICINE

EDUCATION 2000: Ph.D. in Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic

1987: MUDr./M.D. at Faculty of Medicine, Masaryk University, Brno, Czech Republic

TRAINING 2000: Visiting Professor, Hematology-Oncology, Montreal Children´s Hospital, Canada

CLINICAL RESEARCH CORE FACILITIESBASIC RESEARCHTRANSLATIONAL RESEARCH

TOP PUBLICATIONS

MAIN PARTNERS AND COLLABORATING INSTITUTIONS Medical University of Vienna, Vienna, Austria Floating Hospital for Children at Tufts Medical Center, Boston, MA, USA Marseille Public University Hospital, Marseille, France

OFFERED SERVICES AND EXPERTISE Unique and well characterized population of young adults– former pediatric oncology patients who are in risk of late toxicity from the disease and the treatment and who should be looked after and further studied in many areas, mainly cardiology, neurology, endocrinology, pulmonology.

Established cooperation with international pediatric oncology centers in Europe and the US.

BEST RESULTS Establishment of the functional model of national and international cooperation enabling access to full range of personalized precision diagnostics for children with cancer and designation of international pediatric oncology study group around Brno – CEPOETA.org which in cooperation with CZECRIN is the platform to further study personalized, precision pediatric oncology.

GASPAR, N., MARSHALL, L.V., BINNER, D., HEROLD, R. et al. Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE. Annals of Oncology, Mar 2018, 29(3), 766-771.

CAVALII, FMG., REMKE, M., RAMPASEK, L., PEACOCK, J., SHIH, DJH., LUU, B., et al., Intertumoral Heterogenity within Medulloblastoma Subgroups. Cancer Cell. 2017.

MYNAREK, M., PIZER, B., DUFOUR, C., VAN VUURDEN, D., GARAMI, M., MASSIMINO, M., FANGUSARO, J., DAVIDSON, T., GIL DA COSTA, MJ., STERBA, J., BENESCH, M., et al., Evaluation of age-dependent treatment stratedies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data. Neuro-Oncology. 2017, 19(4), 576-585.

CHLAPEK, P., ZITTERBART, K., KREN, L., FILIPOVA, L., STRBA, J., VESELSKA, R., Uniformity under in vitro conditions: Changes in the phenotype of cancer cell lines derived from different medulloblastoma subgroups. Plos One. 2017, 12(2), e0172552.

MUDRY, P., SLABY, O., NERADIL, J., SOUKALOVA, J., MELICHARKOVA, K., ROHLEDER, O., JEZOVA, M., SEEHOFNEROVA, A., MICHU, E., VESELSKA, R., STERBA, J., Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene. BMC Cancer. 2017, 17(1), 119.

St. Anne‘s University Hospital BrnoInternational Clinical Research Center

Pekařská 53, 656 91 Brno | Czech Republic | ID: 00159816Phone: (+420) 543 181 111 | E-mail: icrc@fnusa.cz | www.fnusa-icrc.org

Supported by the project no. LQ1605 Translational Medicine from the National Program of Sustainability II (MEYS CR)

TECHNOLOGICAL EQUIPMENT Mass Spectrometry – CSF proteomic analyzes Phosphoproteomic Facility – phosphoproteomic analyzes High-Performance Liquid Chromatography – sample analyzes

CLINICAL RESEARCHDevelopment of Novel Strategies for Early Diagnostic and Advanced Treatment of Neurological Disorders, Cardiovascular and Oncological Diseases